02:23 PM EDT, 05/30/2024 (MT Newswires) -- Catalyst Pharmaceuticals ( CPRX ) said Thursday that the US Food and Drug Administration approved its supplemental new drug application to increase daily dose of Firdapse, a treatment of Lambert-Eaton myasthenic syndrome, an autoimmune disease.

The FDA approved maximum increase in Firdapse daily dose from 80 milligrams to 100 milligrams for treatment of Lambert-Eaton myasthenic syndrome, or LEMS, in adults and children weighing more than 45 kilograms. Firdapse, or amifampridine, is a potassium channel blocker.

Catalyst Pharmaceuticals ( CPRX ) shares rose nearly 2% in recent trading.

Price: 16.13, Change: +0.25, Percent Change: +1.57